The Inherited Syndromes: Familial Adenomatous Polyposis, Hereditary Nonpolyposis Colorectal Cancer, and the Hamartomatous Polyposes

  • James Church
  • Graham Casey
Chapter
Part of the Developments in Oncology book series (DION, volume 82)

Abstract

There are two main syndromes in which a tendency to develop colorectal cancer is transmitted by dominant inheritance (inheritance that requires the transmission of only one mutated copy of a gene for the disease to become manifest). These syndromes are familial adenomatous polyposis (FAP) and hereditary non-polyposis colorectal cancer (HNPCC). Although they account for <1% and <3% of the entire colorectal cancer burden respectively, these syndromes are important for what they can teach about the mechanisms of colorectal tumorigenesis and for the cancer risk in patients who suffer from them. For these patients, recognition of the syndrome and appropriate screening and surgery are potentially life saving. There are other much less common and less well known dominantly inherited syndromes of colorectal cancer predisposition. These are the hamartomatous polyposes, including Juvenile Polyposis Coli (JPC), Peutz-Jehger’s Syndrome (PJS), Cowden’s Syndrome (CS) and Bannayan-Ruvalcaba-Riley Syndrome (BRR). This chapter is dedicated to a discussion of these dominantly inherited syndromes.

Keywords

Adduct Sarcoma Diarrhea Tamoxifen Myeloma 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Sieber OM, Lipton L, Crabtree M et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. New Engl J Med 2003; 348: 791–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Groden J, Thliveris A, Samowitz W et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991;66:589–600.PubMedCrossRefGoogle Scholar
  3. 3.
    Fearnhead NS, Britton MP, Bodmer WF. The ABC of APC. Hum Mol Genet 2001; 10: 721–33.PubMedCrossRefGoogle Scholar
  4. 4.
    Church JM. Anatomy of a gene: functional correlations of APC mutation. Semin Colon & Rect Surg 1998; 9:49–52.Google Scholar
  5. 5.
    Church J, Burke C, McGannon E, Pastean O, Clark B. Predicting polyposis severity by proctoscopy: how reliable is it? Dis Colon Rectum 2001; 44:1249–54.PubMedCrossRefGoogle Scholar
  6. 6.
    Wu JS, Paul P, McGannon E et al. Association of APC mutations with polyp number in familial adenomatous polyposis. Dis Colon Rectum 1995; 38: A4, 1995.CrossRefGoogle Scholar
  7. 7.
    Winde G, Schmid KW, Schlegel W et al. Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment. Dis Colon Rectum 1995; 38: 813PubMedCrossRefGoogle Scholar
  8. 8.
    Giardello FM, Hamilton SR, Krush AJ et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328; 1313–16, 1993CrossRefGoogle Scholar
  9. 9.
    Thorson AG, Lynch HT, Smyrck TC. Rectal cancer in FAP patient after sulindac. Lancet 343:180, 1994.PubMedCrossRefGoogle Scholar
  10. 10.
    Niv Y, Fraser GM. Adenocarcinoma in the rectal segment in familial polyposis coli is not prevented by sulindac therapy. Gastroenterology 107:854–7, 1994.PubMedCrossRefGoogle Scholar
  11. 11.
    Tsukada K, Church JM, Jagelman DG, et al. Non-cytotoxic drug therapy for intra-abdominal desmoid tumor in patients with familial adenomatous polyposis. Dis Colon Rectum 1992; 35:29–33.PubMedCrossRefGoogle Scholar
  12. 12.
    Steinbach G. Lynch PM. Phillips RK. et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Eng J Med. 2000; 342:1946–52.CrossRefGoogle Scholar
  13. 13.
    Poon R, Smits R, Li C, Jagmohan-Changur S et al. Cyclooxygenase-two (COX-2) modulates proliferation in aggressive fibromatosis (desmoid tumor). Oncogene 2001; 20: 451–60.PubMedCrossRefGoogle Scholar
  14. 14.
    Phillips RK, Wallace MH, Lynch PM, et al. FAP Study Group. A randomized, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 2002; 50: 857–60.PubMedCrossRefGoogle Scholar
  15. 15.
    Scates DK, Venitt S, Phillips RKS et al. High pH reduces in vitro DNA adduct formation by bile from patients with familial adenomatous polyposis: Might antacids reduce duodenal polyposis? Gut 1995; 36: 918–21.PubMedCrossRefGoogle Scholar
  16. 16.
    Wallace MH, Forbes A, Beveridge IG, et al. Randomized, placebo-controlled trial of gastric acid-lowering therapy on duodenal polyposis and relative adduct labeling in familial adenomatous polyposis. Dis Colon Rectum. 2001; 4: 1585–9.CrossRefGoogle Scholar
  17. 17.
    Ording Olsen K, Juul S, Berndtsson I, Oresland T, Laurberg S. Ulcerative colitis: female fecundity before diagnosis, during disease, and after surgery compared with a population sample. Gastroenterology 2002; 122:15–9.CrossRefGoogle Scholar
  18. 18.
    Kartheuser AH, Parc R, Penna CP et al. Ileal pouch-anal anastomosis as the first choice operation in patients with familial adenomatous polyposis: a ten year experience. Surgery 1996; 119:615–23.PubMedCrossRefGoogle Scholar
  19. 19.
    Nugent KP, Phillips RKS. Rectal cancer risk in older patients with familial adenomatous polyposis and an ileorectal anastomosis: a cause for concern. Br J Surg 1992; 79: 1204–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Church JM, McGannon E, Hull-Boiner S et al. Gastroduodenal polyps in patients with familial adenomatous polyposis. Dis Colon Rectum 1992; 35:1170–3.PubMedCrossRefGoogle Scholar
  21. 21.
    Chung RS, Church JM, Van Stolk R. Pancreas-sparing duodenectomy: Indications, surgical technique and results. Surgery 1995;117:254–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Spigelman AD. Familial adenomatous polyposis and the upper gastrointestinal tract. Semin Colon Rectal Surg 1995; 6:26–8.Google Scholar
  23. 23.
    Hartley, J., S. Gupta, E. McGannon, V. Fazio, and J. Church. The significance of incidental desmoids identified during surgery for familial adenomatous polyposis. Dis Colon Rectum 2003; In press.Google Scholar
  24. 24.
    Lynch HT, Fitzgibbons R, Chong S et al. Use of doxorubicin and dacarbazine for the management of unresectable intra-abdominal desmoid tumors in Gardner’s Syndrome. Dis Colon Rectum 1994; 37:260–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Mace J, Biermann JS, Sondak V et al. Response of extraabdominal desmoid tumors to therapy with imatinab mesylate. Cancer 2002; 95: 2373–9PubMedCrossRefGoogle Scholar
  26. 26.
    Church JM. Desmoid tumors in patients with familial adenomatous polyposis. Semin Colon Rectum Surg 1995; 6: 29–32.Google Scholar
  27. 27.
    Chatzipetrou MA, Tzakis AG, Pinna AD, et al. Intestinal transplantation for the treatment of desmoid tumors associated with familial adenomatous polyposis. Surgery 2001; 129: 277–81.PubMedCrossRefGoogle Scholar
  28. 28.
    Clark SK, Smith TG, Katz DE, Reznek RH, Phillips RK. Identification and progression of a desmoid precursor lesion in patients with familial adenomatous polyposis. Br J Surg 1998; 85: 970–3.PubMedCrossRefGoogle Scholar
  29. 29.
    Attanoos R, Billings PJ, Hughes LE, Williams GT. Ileostomy polyps, adenomas, and adenocarcinomas. Gut 1995; 37: 840–4.PubMedCrossRefGoogle Scholar
  30. 30.
    Wu JS, McGannon ES, Church JM. Incidence of neoplastic polyps in the ileal pouch of patients with familial adenomatous polyposis after restorative proctocolectomy. Dis Colon Rectum 1998; 41: 552–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Remzi FH, Church JM, Bast J, et al. Mucosectomy vs. stapled ileal pouch-anal anastomosis in patients with familial adenomatous polyposis: functional outcome and neoplasia control. Dis Colon Rectum 2001; 44:1590–6PubMedCrossRefGoogle Scholar
  32. 32.
    Hamada H, Kurimoto M, Endo S, et al. Turcot’s syndrome presenting with medulloblastoma and familiar adenomatous polyposis: a case report and review of the literature. Acta Neurochirurgica 1998; 140: 631–2.PubMedCrossRefGoogle Scholar
  33. 33.
    Hamilton SR, Liu B, Parsons RE et al. The molecular basis of Turcot’s syndrome. New Engl J Med 1995; 332: 839–47.PubMedCrossRefGoogle Scholar
  34. 34.
    Hernegger GS, Moore HG, Guillem JG. Attenuated familial adenomatous polyposis: an evolving and poorly understood entity. Dis Colon Rectum 2002; 45:127–34PubMedCrossRefGoogle Scholar
  35. 35.
    Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Group on Hereditary Non-polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 1991; 34:424–5.PubMedCrossRefGoogle Scholar
  36. 36.
    Church J, Lowry A, Simmang C. The Standards Task Force, American Society of Colon and rectal Surgeons. Practice parameters for the identification and testing of patients at risk for dominantly inherited colorectal cancer-supporting documentation. Dis Colon Rectum 2001; 44: 1404–12.PubMedCrossRefGoogle Scholar
  37. 37.
    Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch Syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999; 116: 453–6.CrossRefGoogle Scholar
  38. 38.
    Rodriguez-Bigas MA. Boland CR. Hamilton SR. et al. A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. JNC I 1997;89:1758–62.CrossRefGoogle Scholar
  39. 39.
    Lynch HT, Smyrk T, Lynch J. Clinical and molecular genetic aspects of the Lynch Syndromes. Sem Colon Rectal Surg 1995;6:38–47.Google Scholar
  40. 40.
    Watson P, Lynch HT. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 1993; 71: 677–81.PubMedCrossRefGoogle Scholar
  41. 41.
    Church JM. Prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer. Ann Med 1996; 28: 479–82.PubMedCrossRefGoogle Scholar
  42. 42.
    Lynch AC, Church JM, Lavery IC. Quality of life and bowel function after Colectomy and Ileo Rectal anastomosis for colon cancer. Presented at American Society of Colorectal Surgeons Annual Meeting, New Orleans, LA, June, 2003.Google Scholar
  43. 43.
    Jishage K, Nezu J, Kawase Y, et al. Role of LKB1, the causative gene of Peutz-Jehger’s syndrome, in embryogenesis and polyposis. PNAS 2002; 99: 8903–8.PubMedGoogle Scholar
  44. 44.
    Tiainen M, Vaahtomeri K, Ylikorkala A, Makela TP. Growth arrest by the LKB1 tumor suppressor: induction of p21 WAF/CIP1. Hum Mol Genet 2002; 11: 1497–504.PubMedCrossRefGoogle Scholar
  45. 45.
    Rossi DJ, Ylikorkala A, Korsisaari N, et al. Induction of cyclooxygenase-2 in a mouse model of Peutz-Jeghers polyposis. PNAS 2002; 99: 12327–32PubMedCrossRefGoogle Scholar
  46. 46.
    Dunlop MG. Guidance on gastrointestinal surveillance for hereditary non-polyposis colorectal cancer, familial adenomatous polyposis, juvenile polyposis and Peutz-Jehger’s syndrome. Gut 2002; 51 Suppl V, v21–v27.Google Scholar
  47. 47.
    Edwards DP, Khosraviani K, Stafferton R, Phillips RK. Long-term results of polyp clearance by intraoperative enteroscopy in the Peutz-Jeghers syndrome. Dis Colon Rectum 2003; 46:48–50.PubMedCrossRefGoogle Scholar
  48. 48.
    Howe JR, Bair JL, Sayed MG, et al. Germline mutations of the gene encoding bone morphogenic protein receptor 1A in juvenile polyposis. Nature Genet 2001; 28: 184–7.PubMedCrossRefGoogle Scholar
  49. 49.
    Waite KA, Eng C. BMP2 exposure results in decreased PTEN protein degradation and increased PTEN levels. Hum Mol Genet 2003; 12:679–84.PubMedCrossRefGoogle Scholar
  50. 50.
    Waite KA, Eng C. Protean PTEN: form and function. Am J Hum Genet 2002; 70: 829–844.PubMedCrossRefGoogle Scholar
  51. 51.
    Woodford-Richens K, Bevan S, Churchman M, et al. Analysis of genetic and phenotypic heterogeneity in juvenile polyposis. Gut 2000; 46: 656–60.PubMedCrossRefGoogle Scholar
  52. 52.
    Zurawel RH, Allen C, Chiappa S, et al. Analysis of PTCH/SMO/SHH pathway genes in medulloblastoma. Genes, Chr Ca 2000; 27: 44–51.CrossRefGoogle Scholar
  53. 53.
    Whitelaw SC, Murday VA, Tomlinson IP, et al. Clinical and molecular features of the hereditary mixed polyposis syndrome. Gastroenterology 1997; 112: 327–34.PubMedCrossRefGoogle Scholar
  54. 54.
    Thomas HJ, Whitelaw SC, Cottrell SE, et al. Genetic mapping of hereditary mixed polyposis syndrome to chromosome 6q. Am J Hum Genet 1996; 58:770–6.PubMedGoogle Scholar
  55. 55.
    Ramsden KL, Thompson H. The Cronkhite-Canada Syndrome: a seldom recognized entity. Endoscopy 1994; 26: 331–2.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2004

Authors and Affiliations

  • James Church
    • 1
  • Graham Casey
    • 2
  1. 1.Department ofColorectal SurgeryThe Cleveland Clinic FoundationClevelandUSA
  2. 2.Lerner Research InstituteThe Cleveland Clinic FoundationCleveland

Personalised recommendations